Infosys appoints N R Narayana Murthy as executive chairman of the board Infosys announced that the company's board has appointed Mr. N R Narayana Murthy into the board and executive leadership of the company. The board approved appointing Mr. N R Narayana Murthy as Executive Chairman of the Board and Additional Director with effect from June 1. Mr. Murthy's election as a Director would be placed for the consideration of the Company's shareholders in the Annual General Meeting, AGM, on June 15. Subject to his election as a director at the AGM, the Board will take up in its meeting on June 15 the resolutions for convening an extraordinary general meeting within the requisite period, in order to seek approval from the shareholders for appointing him as the Executive Chairman and Whole-time Director for a period of five years commencing on June 1.
News For INFY From The Last 14 Days
Check below for free stories on INFY the last two weeks.
On The Fly: Analyst Downgrade Summary Today's noteworthy downgrades include: Adidas (ADDYY) downgraded to Neutral from Buy at Goldman... Fabrinet (FN) downgraded at B. Riley... Freeport McMoRan (FCX) downgraded at Stifel... Infosys (INFY) downgraded to Hold from Buy at Jefferies... InterMune (ITMN) downgraded to Neutral from Buy at Goldman... Jones Energy (JONE) downgraded to Neutral from Overweight at JPMorgan... LVMH Moet Hennessy (LVMUY) downgraded to Neutral from Buy at Goldman... Madison Square Garden (MSG) downgraded to Hold from Buy at Topeka... Qualys (QLYS) downgraded to Sector Perform from Outperform at RBC Capital... SeaWorld (SEAS) downgraded to Market Perform from Outperform at Wells Fargo... Theravance Biopharma (TBPH) downgraded to Underperform from Neutral at RW Baird... URS Corporation (URS) downgraded to Neutral from Buy at Sterne Agee... ViaSat (VSAT) downgraded to Perform from Outperform at Oppenheimer... Wynn Resorts (WYNN) downgraded to Hold from Buy at Gabelli.
Infosys downgraded to Hold from Buy at Jefferies Jefferies downgraded Infosys last night to Hold citing valuation and a lack of near-term catalysts for revenue growth. The firm lowered its price target for shares to $59 from $60.